
DUEXIS clinical information
Find out more about DUEXIS and how it could benefit your OA and RA patients.
DOWNLOAD INFO1.7 MB
FOR YOUR PATIENTS
Introduce your osteoarthritis (OA) and rheumatoid arthritis (RA) patients to the products in the Horizon Inflammation Care portfolio that are right for them.
Introduce your appropriate OA or RA patients to DUEXIS with this comprehensive brochure.
DOWNLOAD BROCHURE3.3 MB
Introduce your appropriate OA knee pain patients to PENNSAID 2% with this comprehensive brochure.
DOWNLOAD BROCHURE2.6 MB
Introduce your appropriate RA patients to RAYOS with this comprehensive brochure.
DOWNLOAD BROCHURE1.8 MB
CLINICAL INFO
Select your specialty, or the specialty that is most similar to yours, to download information on Horizon Inflammation Care products that has been specifically tailored to your needs.
Find out more about DUEXIS and how it could benefit your OA and RA patients.
DOWNLOAD INFO1.7 MB
Find out more about PENNSAID 2% and how it could benefit your OA knee pain patients.
DOWNLOAD INFO1.2 MB
Find out more about RAYOS and how it could benefit your RA patients.
DOWNLOAD INFO850 KB
Find out more about PENNSAID 2% and how it could benefit your OA knee pain patients.
DOWNLOAD INFO1.2 MB
Find out more about DUEXIS and how it could benefit your OA and RA patients.
DOWNLOAD INFO1.2 MB
Find out more about RAYOS and how it could benefit your RA patients.
DOWNLOAD INFO850 KB
Find out more about RAYOS and how it could benefit your RA patients.
DOWNLOAD INFO671 KB
Find out more about DUEXIS and how it could benefit your OA and RA patients.
DOWNLOAD INFO2.6 MB
Find out more about RAYOS and how it could benefit your RA patients.
DOWNLOAD INFO1 MB
Find out more about DUEXIS and how it could benefit your OA and RA patients.
DOWNLOAD INFO1.2 MB
Find out more about PENNSAID 2% and how it could benefit your OA knee pain patients.
DOWNLOAD INFO1.2 MB
Find out more about PENNSAID 2% and how it could benefit your OA knee pain patients.
DOWNLOAD INFO1.3 MB
Find out more about DUEXIS and how it could benefit your OA and RA patients.
DOWNLOAD INFO1.3 MB
Find out more about RAYOS and how it could benefit your RA patients.
DOWNLOAD INFO642.5 KB
ACCESS SUPPORT
HorizonCares™ is a convenient and cost-effective program for your commercially insured patients to access their Horizon Inflammation Care prescriptions. Download documents about how to submit a Prior Authorization and how HorizonCares works.
Everything you need to start a Prior Authorization for DUEXIS.
213.0 KB
Everything you need to start a Prior Authorization for PENNSAID 2%.
196.0 KB
Everything you need to start a Prior Authorization for RAYOS.
164.0 KB
Learn more about how HorizonCares helps patients get the medication they need quickly and affordably.
92.0 KB
Share this overview of how the HorizonCares program works with your patients.
139.0 KB
TELEMED RESOURCES
Communications to send to patients before their telemedicine visits
Attach in a communication to your patients with OA to encourage them to schedule a telemedicine visit.
DOWNLOAD53 KB
Attach in a communication to your patients with RA to encourage them to schedule a telemedicine visit.
DOWNLOAD46 KB
Attach in a communication to your patients to help them prepare for their telemedicine visit with your practice.
DOWNLOAD53 KB
DURING & AFTER VISIT
DUEXIS RESOURCES
Information to show your osteoarthritis (OA) and rheumatoid arthritis (RA) patients during their telemedicine visits
A guide to use during your telemedicine visits with patients for whom you are prescribing DUEXIS.
DOWNLOAD500 KB
A guide to use during your telemedicine visits with OA patients to help explain their condition.
DOWNLOAD72 KB
A guide to use during your telemedicine visits with RA patients to help explain their condition.
DOWNLOAD68 KB
Communications to send to patients after their telemedicine visits
PENNSAID 2% RESOURCES
Information to show your osteoarthritis (OA) patients during their telemedicine visits
Communications to send to patients after their telemedicine visits
RAYOS RESOURCES
Information to show your rheumatoid arthritis (RA) patients during their telemedicine visits
Communications to send to patients after their telemedicine visits
Start your patients on therapy with samples of a Horizon Inflammation Care product.
Get more information by having your representative come to your practice.
OA=osteoarthritis; RA=rheumatoid arthritis.
DUEXIS® (ibuprofen and famotidine), a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
RAYOS is a corticosteroid indicated:
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
DUEXIS® (ibuprofen and famotidine), a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
RAYOS is a corticosteroid indicated:
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.